首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1473829

聚乙二醇化蛋白質市場

PEGylated Proteins Market

出版日期: 2024年04月29日 | 出版商:

BCC Research | 英文 74 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球聚乙二醇化蛋白市場規模預計將從 2023 年的 102 億美元成長到 2028年終的159 億美元，預測期內複合年成長率為 9.4%。

從地區來看，北美市場預計將從2023年的37億美元成長到2028年底的56億美元，同期複合年成長率為8.9%。歐洲市場預計將從2023年的32億美元成長到2028年終的51億美元，複合年成長率為9.5%。

本報告調查了全球聚乙二醇化蛋白市場，並提供了市場概況、法律制度、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析、競爭格局，我們編制了主要企業。

分類細目
全球聚乙二醇化蛋白質市場：依蛋白質類型
顆粒細胞增生因子(G-CSF)
聚乙二醇化單株抗體
聚乙二醇干擾素
聚乙二醇化重組因子
其他
全球聚乙二醇化蛋白質市場：按聚乙二醇化類型
線性聚乙二醇化蛋白
支鏈聚乙二醇化蛋白
全球聚乙二醇化蛋白質市場：按聚乙二醇化應用
自體免疫疾病
血
癌症
其他
全球聚乙二醇化蛋白市場：按地區
北美洲
歐洲
亞太地區
其他地區

第6章競爭訊息

近期趨勢
臨床試驗活動

第 7 章聚乙二醇化蛋白市場的永續性：ESG 視角

聚乙二醇化蛋白質產業的永續性
了解 ESG資料
環保性能
社會表現
管治績效
BCC的結語

第8章附錄

調查方法
來源
簡稱
公司簡介
AMGEN INC.
F. HOFFMANN-LA ROCHE LTD.
MERCK KGAA
PFIZER INC.
SANDOZ GROUP AG

簡介目錄圖表

Product Code: BIO253A

The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.

North American market for PEGylated proteins is expected to grow from $3.7 billion in 2023 and projected to reach $5.6 billion by the end of 2028, at a CAGR of 8.9% during the forecast period of 2023 to 2028.

The European market for PEGylated proteins is expected to grow from $3.2 billion in 2023 and projected to reach $5.1 billion by the end of 2028, at a CAGR of 9.5% during the forecast period of 2023 to 2028.

Report Scope

This report highlights the current and future market potential of PEGylated proteins and provides a detailed analysis of the drivers, restraints, and opportunities in this market. The report also surveys the competitive environment for PEGylated proteins, including coverage of the pipeline activities adopted by players in this market, and it includes market projections for 2028. Also included are company profiles of key players featuring detailed information about each company's business segments, financials, product portfolios and recent developments. The report does not cover PEGylated vaccines.

In this report, the global market for PEGylated proteins market is segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World. For market estimates, data is provided for 2020 and 2021 (which serve as the historic years), for 2022 (the base year), and forecast for 2028.

Report Includes

41 data tables and 22 additional tables
Analysis of the PEGylated proteins market
Analyses of global market trends, with revenue data for 2021-2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2028
Estimates of the current market size and revenue growth prospects, along with a market share analysis by product and services, protein type, application, and region
Facts and figures pertaining to the market drivers, opportunities and restraints, and the impact of macroeconomic variables
An analysis of recent patent grants and published patents
A look at emerging technologies and regulatory issues
Overview of sustainability trends and ESG developments, including consumer attitudes, companies' ESG score rankings and their ESG practices
Insight into the competitive landscape, including companies' market shares, business segments, financials and product portfolios, as well as recent M&A activity and venture funding outlook
Profiles of the major market players

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Introduction
Advantages of Protein PEGylation
Limitations of PEGylated Therapeutics

Chapter 3 Market Dynamics

Market Dynamics Snapshot
Market Drivers
Protein Drugs in Hematology and Oncology
Design of Biobetters
Market Restraints
Immunogenicity and Side Effects
Formulation Challenges
Market Opportunities
Site-Specific PEGylation
New Indications and Formulation Techniques

Chapter 4 Emerging Technologies and Developments

Introduction
Non-Covalent PEGylation
PEGylation of Nanoparticles
Antibody-Drug Conjugates (ADCs)

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Global PEGylated Proteins Market, by Protein Type
Granulocyte-Colony Stimulating Factors (G-CSF)
PEGylated Monoclonal Antibodies
PEGylated Interferons
PEGylated Recombinant Factors
Other Protein Types
Global PEGylated Proteins Market, by PEGylation Type
Linear PEGylated Proteins
Branched PEGylated Proteins
Global PEGylated Proteins Market, by PEGylation Application
Autoimmune Diseases
Hematology
Cancer
Other Applications
Geographic Breakdown
Global Market for PEGylated Proteins, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence

Recent Developments in the PEGylated Proteins Market
Clinical Trial Activities

Chapter 7 Sustainability in the PEGylated Proteins Market: ESG Perspective

Introduction
Sustainability in the PEGylated Proteins Industry
Understanding the ESG Data
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC

Chapter 8 Appendix

Methodology
Sources
Abbreviations
Company Profiles
AMGEN INC.
F. HOFFMANN-LA ROCHE LTD.
MERCK KGAA
PFIZER INC.
SANDOZ GROUP AG

簡介目錄圖表

List of Tables

Summary Table : Global Market for PEGylated Proteins, by Region, Through 2028
Table 1 : PEGylated Drugs in Clinical Trials for Cancer
Table 2 : Discontinued PEGylated Drugs in Clinical Trials
Table 3 : Side Effects Observed with Approved Products
Table 4 : Global Market for PEGylated Proteins, by Protein Type, Through 2028
Table 5 : Marketed PEGylated G-CSF Drugs
Table 6 : Global Market for G-CSF, by Region, Through 2028
Table 7 : Global Market for PEGylated mAbs, by Region, Through 2028
Table 8 : Global Market for PEGylated Interferons, by Region, Through 2028
Table 9 : Global Market for PEGylated Recombinant Factors, by Region, Through 2028
Table 10 : Global Market for Other Protein Types, by Region, Through 2028
Table 11 : Global Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 12 : Global Market for Linear PEGylated Proteins, by Region, Through 2028
Table 13 : Global Market for Branched PEGylated Proteins, by Region, Through 2028
Table 14 : Global Market for PEGylated Proteins, by Application, Through 2028
Table 15 : Global Market for PEGylated Proteins for Autoimmune Diseases, by Region, Through 2028
Table 16 : Global Market for PEGylated Proteins for Hematology, by Region, Through 2028
Table 17 : Global Market for PEGylated Proteins for Cancer, by Region, Through 2028
Table 18 : Global Market for PEGylated Proteins for Other Applications, by Region, Through 2028
Table 19 : Global Market for PEGylated Proteins, by Region, Through 2028
Table 20 : North American Market for PEGylated Proteins, by Country, Through 2028
Table 21 : North American Market for PEGylated Proteins, by Protein Type, Through 2028
Table 22 : North American Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 23 : North American Market for PEGylated Proteins, by Application, Through 2028
Table 24 : European Market for PEGylated Proteins, by Country, Through 2028
Table 25 : European Market for PEGylated Proteins, by Protein Type, Through 2028
Table 26 : European Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 27 : European Market for PEGylated Proteins, by Application, Through 2028
Table 28 : Asia-Pacific Market for PEGylated Proteins, by Country, Through 2028
Table 29 : Asia-Pacific Market for PEGylated Proteins, by Protein Type, Through 2028
Table 30 : Asia-Pacific Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 31 : Asia-Pacific Market for PEGylated Proteins, by Application, Through 2028
Table 32 : RoW Market for PEGylated Proteins, by Protein Type, Through 2028
Table 33 : RoW Market for PEGylated Proteins, by PEGylation Type, Through 2028
Table 34 : RoW Market for PEGylated Proteins, by Application, Through 2028
Table 35 : Recent Developments in PEGylated Proteins Market, 2022 and 2023
Table 36 : Competitor Clinical Trial Activities in PEGylated Protein Therapeutics, by Phase, 2023
Table 37 : ESG Risk Rankings for Major PEGylated Protein Drug Companies*
Table 38 : ESG: Environmental Overview
Table 39 : ESG: Social Overview
Table 40 : ESG: Governance Overview
Table 41 : Report Sources
Table 42 : Abbreviations Used in this Report
Table 43 : Amgen Inc.: Company Snapshot
Table 44 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 45 : Amgen Inc.: Product Portfolio
Table 46 : Amgen Inc.: News/Key Developments, 2023
Table 47 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 48 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 49 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 50 : Merck KGaA: Company Snapshot
Table 51 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 52 : Merck KGaA: Product Portfolio
Table 53 : Merck KGaA: News/Key Developments, 2022 and 2023
Table 54 : Pfizer Inc.: Company Snapshot
Table 55 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 56 : Pfizer Inc.: Product Portfolio
Table 57 : Pfizer Inc.: News/Key Developments, 2023
Table 58 : Sandoz Group AG: Company Snapshot
Table 59 : Sandoz Group AG: Financial Performance, FY 2022 and 2023
Table 60 : Sandoz Group AG: Product Portfolio
Table 61 : Sandoz Group AG: News/Key Developments, 2023

List of Figures

Summary Figure : Global Market for PEGylated Proteins, by Region, 2020-2028
Figure 1 : Advantages of Protein PEGylation
Figure 2 : Timeline of PEGylated Protein Therapeutics
Figure 3 : Disadvantages of PEGylated Protein Therapeutics
Figure 4 : Market Dynamics of Global PEGylated Proteins
Figure 5 : Emerging Technologies in the PEGylated Proteins Market
Figure 6 : Global Market Shares of PEGylated Proteins, by Protein Type, 2022
Figure 7 : Global Market for G-CSF, by Region, 2020-2028
Figure 8 : Global Market for PEGylated mAbs, by Region, 2020-2028
Figure 9 : Global Market for PEGylated Interferons, by Region, 2020-2028
Figure 10 : Global Market for PEGylated Recombinant Factors, by Region, 2020-2028
Figure 11 : Global Market for Other Protein Types, by Region, 2020-2028
Figure 12 : Global Market Shares of PEGylated Proteins, by PEGylation Type, 2022
Figure 13 : Global Market for Linear PEGylated Proteins, 2020-2028
Figure 14 : Global Market for Linear PEGylated Proteins, by Region, 2020-2028
Figure 15 : Global Market for Branched PEGylated Proteins, 2020-2028
Figure 16 : Global Market for Branched PEGylated Proteins, by Region, 2020-2028
Figure 17 : Global Market Shares of PEGylated Proteins, by Application, 2022
Figure 18 : Global Market for PEGylated Proteins for Autoimmune Diseases, 2020-2028
Figure 19 : Global Market for PEGylated Proteins for Autoimmune Diseases, by Region, 2020-2028
Figure 20 : Global Market for PEGylated Proteins for Hematology, 2020-2028
Figure 21 : Global Market for PEGylated Proteins for Hematology, by Region, 2020-2028
Figure 22 : Global Market for PEGylated Proteins for Cancer, 2020-2028
Figure 23 : Global Market for PEGylated Proteins for Cancer, by Region, 2020-2028
Figure 24 : Global Market for PEGylated Proteins for Other Applications, 2020-2028
Figure 25 : Global Market for PEGylated Proteins for Other Applications, by Region, 2020-2028
Figure 26 : Global Market Shares of PEGylated Proteins, by Region, 2022
Figure 27 : Global Market for PEGylated Proteins, by Region, 2020-2028
Figure 28 : North American Market Shares of PEGylated Proteins, by Country, 2022
Figure 29 : European Market Shares of PEGylated Proteins, by Country, 2022
Figure 30 : Asia-Pacific Market Shares of PEGylated Proteins, by Country, 2022
Figure 31 : Snapshot of ESG Pillars
Figure 32 : Advantages of ESG for Companies
Figure 33 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 34 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 35 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 36 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 37 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 38 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 39 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Figure 40 : Sandoz Group AG: Revenue Share, by Business Unit, FY 2023
Figure 41 : Sandoz Group AG: Revenue Share, by Country/Region, FY 2023